Trial Profile
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed By an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Carcinoma; Early breast cancer
- Focus Registrational; Therapeutic Use
- 20 Mar 2024 Planned End Date changed from 1 Dec 2038 to 1 Apr 2025.
- 19 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2038.
- 15 May 2023 Updated Results(of ten years) assessing efficacy of Extended Letrozole Therapy in Early-stage Breast Cancer published in the Journal of the National Cancer Institute